Replies to post #36531 on Biotech Values

[Biowatch]

BMY three year data on BARACLUDE

http://biz.yahoo.com/prnews/061030/nym045.html?.v=73

Three-Year Data Showed Low Incidence of BARACLUDE(R) (Entecavir) Resistance in Nucleoside-Naive Chronic Hepatitis B Patients
Monday October 30, 3:15 pm ET
Data Also Showed Higher Incidence of Resistance Over Three Years in Lamivudine-Refractory Patients

http://biz.yahoo.com/prnews/061030/nym043.html?.v=76

BARACLUDE(R) (Entecavir) Demonstrated Viral Suppression to Undetectable Levels in Most Patients in a Three-Year Cohort
Monday October 30, 3:00 pm ET
90 Percent of Nucleoside-Naive Chronic Hepatitis B E-Antigen (HBeAg) Positive Patients in this Three-Year Cohort Achieved Undetectable Viral Load Levels at 144 Weeks